TheraRadar
Data updated: May 26, 2026

METAXALONE

Musculoskeletal Approved 2010-03-31

Metaxalone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

Source: FDA Label • SCIEGEN PHARMS
9
Indications
--
Phase 3 Trials
16
Years on Market

Details

Status
Prescription
First Approved
2010-03-31
Patent Cliff
2043

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
TABLET

METAXALONE Approval History

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
29 FDA actions from 2010 to 2025
May 2025 SUPPL
Label · Labeling
May 2025 SUPPL
Label · Labeling
Mar 2025 SUPPL
Label · Labeling

What METAXALONE Treats

9 FDA approvals

Originally approved for its first indication in 2010 . Covers 9 distinct patient populations.

  • Other (9)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03068897 results posted 2017-7566 Ph 4 completed Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

METAXALONE FDA Label Details

Indications & Usage

FDA Label (PDF)

Metaxalone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

View full patent landscape →
1 OB patents · 1 families · 4 international docs across 1 countries

METAXALONE Patents & Exclusivity

Latest Patent: May 2043

Patents (2 active)

US12485111 Expires May 14, 2043
US11918559 Expires Jul 29, 2039
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for METAXALONE

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2043
  • 2 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.